171 related articles for article (PubMed ID: 28246027)
1. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy.
Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D
Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.
Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W
J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy.
Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D
Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497
[TBL] [Abstract][Full Text] [Related]
4. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
6. [Newcastle disease virus enhances tumoricidal activity of mouse NK cells against mouse Novikoff hepatoma cells via up-regulating expression of TRAIL on the NK cells].
Song D; Liang Y; Fan X; Yin J; Gong J; Lai Z; Gao L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):599-604. PubMed ID: 25940284
[TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.
An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G
J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066
[TBL] [Abstract][Full Text] [Related]
10. TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro.
Song DZ; Liang Y; Xiao Q; Yin J; Gong JL; Lai ZP; Zhang ZF; Gao LX; Fan XH
Anat Rec (Hoboken); 2013 Oct; 296(10):1552-60. PubMed ID: 23959779
[TBL] [Abstract][Full Text] [Related]
11. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
13. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.
Elankumaran S; Rockemann D; Samal SK
J Virol; 2006 Aug; 80(15):7522-34. PubMed ID: 16840332
[TBL] [Abstract][Full Text] [Related]
14. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
15. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.
Galal El-Shemi A; Mohammed Ashshi A; Oh E; Jung BK; Basalamah M; Alsaegh A; Yun CO
Gene Ther; 2018 Jan; 25(1):54-65. PubMed ID: 28925992
[TBL] [Abstract][Full Text] [Related]
19. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
Altomonte J; Marozin S; Schmid RM; Ebert O
Mol Ther; 2010 Feb; 18(2):275-84. PubMed ID: 19809404
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
